HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zoloft formulary placement (correction)

Executive Summary

In a story on Medicare Part D formulary placement of antidepressants, "The Pink Sheet" incorrectly stated that Pfizer's Zoloft (sertraline) is not covered by Medco's YOURx Plan (1"The Pink Sheet" Dec. 19, 2005, p. 19). The agent is covered on Tier 2 of the plan's formulary with quantity limits. Consequently, Zoloft is covered on the lowest brand cost-sharing tier of five of the nine nationwide plans reviewed...

You may also be interested in...



Branded Antidepressants Face Challenges With Part D Formulary Positions

The Centers for Medicare & Medicaid Services appears to be interpreting its "all or substantially all" policy for Part D plan coverage of antidepressants as allowing sponsors to include the majority of agents on high cost-sharing tiers, according to analysis of plan formularies conducted by "The Pink Sheet."

Second EU MDR Notified Body Designated In France

Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.

Takeda, Astellas Found New JV To Support Japanese Bioventures

Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046721

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel